Jorgen Carlsson

Summary

Affiliation: Uppsala University
Country: Sweden

Publications

  1. doi request reprint Potential for clinical radionuclide-based imaging and therapy of common cancers expressing EGFR-family receptors
    Jorgen Carlsson
    Unit of Biomedical Radiation Sciences, Department of Radiology, Oncology and Radiation Science, Rudbeck Laboratory, Uppsala University, SE 751 85 Uppsala, Sweden
    Tumour Biol 33:653-9. 2012
  2. ncbi request reprint Ligand liposomes and boron neutron capture therapy
    Jorgen Carlsson
    Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    J Neurooncol 62:47-59. 2003
  3. ncbi request reprint Conjugate chemistry and cellular processing of EGF-dextran
    J Carlsson
    Unit of Biomedical Radiation Sciences, Uppsala University, Sweden
    Acta Oncol 38:313-21. 1999
  4. ncbi request reprint Early effects of low dose-rate radiation on cultured tumor cells
    Jorgen Carlsson
    Division of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Cancer Biother Radiopharm 18:663-70. 2003
  5. ncbi request reprint Therapy with radiopharmaceuticals
    Jorgen Carlsson
    Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Uppsala, Sweden
    Acta Oncol 41:623-8. 2002
  6. ncbi request reprint Radiation therapy through activation of stable nuclides
    Jorgen Carlsson
    Department of Oncology, Radiology and Clinicical Immunology, Uppsala University, Uppsala, Sweden
    Acta Oncol 41:629-34. 2002
  7. pmc HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review
    J Carlsson
    Department of Oncology, Uppsala University Hospital, SE 751 85 Uppsala, Sweden
    Br J Cancer 90:2344-8. 2004
  8. ncbi request reprint Planning for intracavitary anti-EGFR radionuclide therapy of gliomas. Literature review and data on EGFR expression
    J Carlsson
    Unit of Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    J Neurooncol 77:33-45. 2006
  9. pmc Requirements regarding dose rate and exposure time for killing of tumour cells in beta particle radionuclide therapy
    Jorgen Carlsson
    Division of Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, SE 751 85, Uppsala, Sweden
    Eur J Nucl Med Mol Imaging 33:1185-95. 2006
  10. ncbi request reprint [(111)In]Bz-DTPA-hEGF: Preparation and in vitro characterization of a potential anti-glioblastoma targeting agent
    Asa Liljegren Sundberg
    Division of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Cancer Biother Radiopharm 18:643-54. 2003

Detail Information

Publications82

  1. doi request reprint Potential for clinical radionuclide-based imaging and therapy of common cancers expressing EGFR-family receptors
    Jorgen Carlsson
    Unit of Biomedical Radiation Sciences, Department of Radiology, Oncology and Radiation Science, Rudbeck Laboratory, Uppsala University, SE 751 85 Uppsala, Sweden
    Tumour Biol 33:653-9. 2012
    ..Possible strategies for radionuclide-based imaging and therapy are briefly discussed, especially in relation to the receptor expression in metastases...
  2. ncbi request reprint Ligand liposomes and boron neutron capture therapy
    Jorgen Carlsson
    Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    J Neurooncol 62:47-59. 2003
    ....
  3. ncbi request reprint Conjugate chemistry and cellular processing of EGF-dextran
    J Carlsson
    Unit of Biomedical Radiation Sciences, Uppsala University, Sweden
    Acta Oncol 38:313-21. 1999
    ..Different intracellular 'traffic routes' for the radionuclides are discussed as well as applications for both imaging and therapy...
  4. ncbi request reprint Early effects of low dose-rate radiation on cultured tumor cells
    Jorgen Carlsson
    Division of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Cancer Biother Radiopharm 18:663-70. 2003
    ..Thus, there seemed to be no obvious relation between HRS and early cellular effects when the cells were analyzed after continuous LDR exposure...
  5. ncbi request reprint Therapy with radiopharmaceuticals
    Jorgen Carlsson
    Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Uppsala, Sweden
    Acta Oncol 41:623-8. 2002
    ..The present report deals with therapy with radiopharmaceuticals...
  6. ncbi request reprint Radiation therapy through activation of stable nuclides
    Jorgen Carlsson
    Department of Oncology, Radiology and Clinicical Immunology, Uppsala University, Uppsala, Sweden
    Acta Oncol 41:629-34. 2002
    ..This report deals with radiation therapy using activation of stable nuclides...
  7. pmc HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review
    J Carlsson
    Department of Oncology, Uppsala University Hospital, SE 751 85 Uppsala, Sweden
    Br J Cancer 90:2344-8. 2004
    ..The stability in HER2 expression is encouraging for efforts to develop complementary forms of therapy, for example, therapy with radionuclide-labelled Trastuzumab...
  8. ncbi request reprint Planning for intracavitary anti-EGFR radionuclide therapy of gliomas. Literature review and data on EGFR expression
    J Carlsson
    Unit of Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    J Neurooncol 77:33-45. 2006
    ..Instead, it is likely that the penetration properties of the targeting agents are critical, and detailed studies on this are urgent...
  9. pmc Requirements regarding dose rate and exposure time for killing of tumour cells in beta particle radionuclide therapy
    Jorgen Carlsson
    Division of Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, SE 751 85, Uppsala, Sweden
    Eur J Nucl Med Mol Imaging 33:1185-95. 2006
    ..The purpose of this study was to identify combinations of dose rate and exposure time that have the potential to provide curative treatment with targeted radionuclide therapy applying low dose rate beta irradiation...
  10. ncbi request reprint [(111)In]Bz-DTPA-hEGF: Preparation and in vitro characterization of a potential anti-glioblastoma targeting agent
    Asa Liljegren Sundberg
    Division of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Cancer Biother Radiopharm 18:643-54. 2003
    ..5% at 24 and 45 hours, respectively. The dissociation constant was estimated to 2.0 nM. The results indicate that [(111)In]benzyl-DTPA-hEGF is a potential candidate for targeting glioblastoma cells, possibly using locoregional injection...
  11. ncbi request reprint Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice
    Ann Charlott Steffen
    Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Eur J Nucl Med Mol Imaging 33:631-8. 2006
    ..The purpose of this study was to investigate the in vivo properties of the new targeting agent...
  12. ncbi request reprint Development of EGF-conjugated liposomes for targeted delivery of boronated DNA-binding agents
    Erika Bohl Kullberg
    Division of Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University S 751 85 Uppsala, Sweden
    Bioconjug Chem 13:737-43. 2002
    ..The conjugate was shown to have EGF-receptor-specific cellular binding in cultured human glioma cells...
  13. ncbi request reprint Treatment of cultured glioma cells with the EGFR-TKI gefitinib ("Iressa", ZD1839) increases the uptake of astatinated EGF despite the absence of gefitinib-mediated growth inhibition
    Asa Liljegren Sundberg
    Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Eur J Nucl Med Mol Imaging 30:727-9. 2003
    ..This indicates that a combination of gefitinib treatment and radionuclide targeting to EGFR might be a useful therapeutic modality, even for patients who do not respond to treatment with gefitinib alone...
  14. ncbi request reprint Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors
    Irina Velikyan
    Department of Organic Chemistry, Institute of Chemistry, Biomedical Centre, Uppsala University, Uppsala, Sweden
    J Nucl Med 46:1881-8. 2005
    ..The aim of this study was to develop a method for preparation of a positron-emitting tracer based on a natural ligand to EGFR, the recombinant human epidermal growth factor (hEGF), and to perform a preclinical evaluation of the tracer...
  15. ncbi request reprint Quantification of internalization of EGFR-binding Affibody molecules: Methodological aspects
    Lovisa Göstring
    Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, SE 751 85 Uppsala, Sweden
    Int J Oncol 36:757-63. 2010
    ..The internalized fraction showed that both the monomeric and dimeric Affibody molecules are expected to give good uptake and thereby good retention of metallic radionuclides which will render good tumor to background values...
  16. ncbi request reprint Introductory experiments on ligand liposomes as delivery agents for boron neutron capture therapy
    Erika Bohl Kullberg
    Division of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, 75185 Uppsala, Sweden
    Int J Oncol 23:461-7. 2003
    ..Thus, it seems possible to kill micro-invasive tumour cells with targeted liposomes if the delivery conditions are optimal...
  17. ncbi request reprint Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule
    Erika Nordberg
    Rudbeck Laboratory, Department of Oncology, Radiology and Clinical Immunology, Biomedical Radiation Sciences, Uppsala University, SE 751 85 Uppsala, Sweden
    Nucl Med Biol 34:609-18. 2007
    ..This new and small molecule is aimed for applications in nuclear medicine. The natural ligand epidermal growth factor (EGF) and the antibody cetuximab were studied for comparison...
  18. ncbi request reprint Biodistribution of 211At labeled HER-2 binding affibody molecules in mice
    Ann Charlott Steffen
    Unit of Biomedical Radiation Sciences, Department of Oncology, Rudbeck Laboratory, Uppsala University, SE 751 85 Uppsala, Sweden
    Oncol Rep 17:1141-7. 2007
    ..However, the labeling chemistry affects the distribution in normal organs to a high degree and needs to be improved to allow clinical use...
  19. ncbi request reprint [177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts
    Mikael Persson
    Department of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, SE 75185 Uppsala, Sweden
    Cancer Res 67:326-31. 2007
    ..0001; and (177)Lu-labeled irrelevant antibody, P < 0.01). No adverse side effects of the treatment could be detected. Thus, the experimental results support the planning of clinical studies applying [(177)Lu]pertuzumab for therapy...
  20. ncbi request reprint A new antibody recognizing the vIII mutation of human epidermal growth factor receptor
    Linda Ohman
    Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Uppsala, Sweden
    Tumour Biol 23:61-9. 2002
    ..The new antibody is a candidate for radioimmunotargeting aiming at diagnostic and therapeutic applications...
  21. doi request reprint Nuclisome: a novel concept for radionuclide therapy using targeting liposomes
    Amelie Fondell
    Department of Oncology, Radiology, and Clinical Immunology, Unit of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, 75185 Uppsala, Sweden
    Eur J Nucl Med Mol Imaging 37:114-23. 2010
    ..We have developed a new two-step targeting strategy to transport (125)I into cancer-cell nuclei using PEG-stabilized tumour-cell targeting liposomes named "Nuclisome-particles"...
  22. ncbi request reprint [(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells
    Mikael Persson
    Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Eur J Nucl Med Mol Imaging 32:1457-62. 2005
    ..The purpose of this study was to analyse whether pertuzumab retains HER-2 targeting capacity after labelling with the therapeutically interesting beta emitter (177)Lu and to make initial characterizations in vitro and in vivo...
  23. ncbi request reprint Radiobromination of monoclonal antibody using potassium [76Br] (4 isothiocyanatobenzyl-ammonio)-bromo-decahydro-closo-dodecaborate (Bromo-DABI)
    Alexander Bruskin
    Unit of Biomedical Radiation Sciences, Rudbecklaboratoriet, Uppsala University, S 751 85, Uppsala, Sweden
    Nucl Med Biol 31:205-11. 2004
    ..The results of the study demonstrated feasibility for using derivatives of closo-dodecaborate in indirect labeling of antibodies for radioimmunoPET...
  24. doi request reprint Differences in radiosensitivity between three HER2 overexpressing cell lines
    Ann Charlott Steffen
    Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, 751 85, Sweden
    Eur J Nucl Med Mol Imaging 35:1179-91. 2008
    ..Therefore, it is of interest to analyse whether HER2 overexpressing tumour cells have different inherent radiosensitivity...
  25. ncbi request reprint [177Lu]Bz-DTPA-EGF: Preclinical characterization of a potential radionuclide targeting agent against glioma
    Asa Liljegren Sundberg
    Division of Biomedical Radiation Sciences, Uppsala University, Uppsala, Sweden
    Cancer Biother Radiopharm 19:195-204. 2004
    ..In conclusion, [177Lu]Bz-DTPA-EGF seems to be a promising candidate for locoregional treatment of glioblastoma due to its high binding affinity, low molecular weight, and ability to target EGFR in vivo...
  26. ncbi request reprint First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule
    Jens Sorensen
    Nuclear Medicine and PET, Department of Radiology, Oncology, and Radiation Sciences, Uppsala University, Uppsala, Sweden
    J Nucl Med 55:730-5. 2014
    ..This study evaluated the distribution, safety, dosimetry, and efficacy of (111)In-ABY-025 for determining the HER2 status in metastatic breast cancer...
  27. ncbi request reprint Cellular retention of radioactivity and increased radiation dose. Model experiments with EGF-dextran
    Asa Liljegren Sundberg
    Division of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Sweden
    Nucl Med Biol 30:303-15. 2003
    ..Thus, dextran seems suitable as a carrier of radionuclides aimed for therapy and gives potential for a highly increased radiation dose...
  28. doi request reprint Dimeric HER2-specific affibody molecules inhibit proliferation of the SKBR-3 breast cancer cell line
    Lina Ekerljung
    Department of Oncology, Radiology and Clinical Immunology, Division of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, SE 751 85 Uppsala, Sweden
    Biochem Biophys Res Commun 377:489-94. 2008
    ..The dimeric (Z(HER2:4))(2) and (Z(HER2:342))(2) both reduced growth of SKBR-3 cells and may prove therapeutically useful either by themselves or as carriers of radionuclides or other cytotoxic agents...
  29. ncbi request reprint Cellular uptake of radioiodine delivered by trastuzumab can be modified by the addition of epidermal growth factor
    Erika Nordberg
    Division of Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, 751 85, Uppsala, Sweden
    Eur J Nucl Med Mol Imaging 32:771-7. 2005
    ..125I was used as a marker for the diagnostically and therapeutically more interesting isotopes 123I (SPECT), 124I (PET) and 131I (therapy)...
  30. ncbi request reprint A novel 125I-labeled daunorubicin derivative for radionuclide-based cancer therapy
    Ludger M Ickenstein
    Department of Physical and Analytical Chemistry, Uppsala University, P O Box 579, 75121 Uppsala, Sweden
    Nucl Med Biol 33:773-83. 2006
    ..The effectiveness of Auger electrons is strongly dependent on their proximity to DNA and is therefore considered as harmless outside the nucleus...
  31. ncbi request reprint Internalisation and retention of EGF-dextran associated radioactivity in transfected Chinese hamster ovary cells expressing the human EGF-receptor
    Pär Olsson
    Division of Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, SE 751 85 Uppsala, Sweden
    Int J Oncol 20:1057-63. 2002
    ..No major differences between the two EGFR expressing cell lines were found and, based on the results in this work, CHO-EGFR cells seem an adequate model for experiments with agents targeting the EGF-receptor...
  32. ncbi request reprint Comparative biodistribution of potential anti-glioblastoma conjugates [111In]DTPA-hEGF and [111In]Bz-DTPA-hEGF in normal mice
    Vladimir Tolmachev
    Division of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Cancer Biother Radiopharm 19:491-501. 2004
    ..However, indium uptake in the case of [111In]DTPA-hEGF was significantly higher in the kidneys and bones. In conclusion, [111In]Bz-DTPA-hEGF seems to have more favourable in vivo distribution in comparison to [111In]DTPA-hEGF...
  33. ncbi request reprint Targeting against epidermal growth factor receptors. Cellular processing of astatinated EGF after binding to cultured carcinoma cells
    Anna Orlova
    Division of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Anticancer Res 24:4035-41. 2004
    ..g. epidermal growth factor (EGF) the receptors of which are overexpressed in many malignancies. However, almost no information concerning the cellular processing of astatinated targeting agents is available...
  34. ncbi request reprint Effects of HER2-binding affibody molecules on intracellular signaling pathways
    Lina Ekerljung
    Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala, Sweden
    Tumour Biol 27:201-10. 2006
    ..HER2, which is overexpressed in 25-30% of human breast cancers, is a tyrosine kinase receptor critical for the signal transduction network that regulates proliferation, migration and apoptosis of cells...
  35. pmc Application of the multicellular tumour spheroid model to screen PET tracers for analysis of early response of chemotherapy in breast cancer
    Azita Monazzam
    Institute of Oncology, Institute of Oncology, Radiology and Clinical Immunology, Uppsala University Hospital, SE 751 85 Uppsala, Sweden
    Breast Cancer Res 9:R45. 2007
    ..The aim of this study was to introduce multicellular tumour spheroids (MTS) to study the effect of anticancer drugs and suggest an appropriate PET tracer for further studies...
  36. ncbi request reprint In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics
    Ann Charlott Steffen
    Unit of Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Cancer Biother Radiopharm 20:239-48. 2005
    ..125I was used in this study as a surrogate marker for the diagnostically relevant radioisotopes 123I for single photon emission computed tomography (SPECT)/gamma-camera imaging and 124I for positron emission tomography (PET)...
  37. ncbi request reprint Effects of radiation on growth of two human tumour cell lines surviving a previous high dose, low dose-rate, radionuclide exposure
    Lova Segerström
    Unit of Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, SE 751 85 Uppsala, Sweden
    Int J Oncol 33:341-9. 2008
    ..The conclusion is that tumour cells surviving high dose, low dose-rate, radionuclide therapy, afterwards can react differently to a new radiation exposure...
  38. ncbi request reprint Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF
    Asa Liljegren Sundberg
    Division of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Eur J Nucl Med Mol Imaging 30:1348-56. 2003
    ..These results indicate that combined treatment with gefitinib might increase the effect of ligand-mediated radionuclide therapy in gefitinib-resistant tumours and decrease the effect of such therapy in gefitinib-sensitive tumours...
  39. ncbi request reprint A limiting factor for the progress of radionuclide-based cancer diagnostics and therapy--availability of suitable radionuclides
    Vladimir Tolmachev
    Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Acta Oncol 43:264-75. 2004
    ..To secure continued development and to meet the foreseen requirements for radionuclide availability from the medical community it is necessary to establish specialized cyclotron centres for radionuclide production...
  40. ncbi request reprint Biological response to radiation therapy
    Ingela Turesson
    Unit of Oncology, Uppsala University, Uppsala, Sweden
    Acta Oncol 42:92-106. 2003
    ....
  41. ncbi request reprint Development and in vitro studies of epidermal growth factor-dextran conjugates for boron neutron capture therapy
    L Gedda
    Department of Diagnostic Radiology, Uppsala University, Sweden
    Bioconjug Chem 7:584-91. 1996
    ..Theoretical calculations show that about 10(3) boron atoms per EGF-based conjugate are needed to give a satisfactory therapeutic response. These conjugates are within reach of that level...
  42. ncbi request reprint Effects of dextranation on the pharmacokinetics of short peptides. A PET study on mEGF
    Q Zhao
    Biomedical Radiation Sciences, Box 535, Uppsala University, S 751 21 Uppsala, Sweden
    Bioconjug Chem 10:938-46. 1999
    ..In conclusion, dextranation affects the biodistribution of mEGF in vivo giving a prolonged circulation time, a decreased uptake in kidney, and an increased spleen accumulation...
  43. ncbi request reprint Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases
    Truls Gårdmark
    Division of Urology, Department of Surgical Sciences, Akademiska Hospital, Uppsala University, Sweden
    BJU Int 95:982-6. 2005
    ....
  44. ncbi request reprint Tumour therapy with radionuclides: assessment of progress and problems
    Jorgen Carlsson
    Department of Oncology, Radiology and Clinical Oncology, Uppsala University Hospital, SE 751 85 Uppsala, Sweden
    Radiother Oncol 66:107-17. 2003
    ..This is especially important in targeted radionuclide therapy where the dose rates often are lower than 1Gy/h...
  45. ncbi request reprint Sensitizing and protective substances in radiation therapy and predictive assays
    Björn Zackrisson
    Department of Oncology, Umea University, Umea, Sweden
    Acta Oncol 41:615-22. 2002
    ..The present report deals with the use of sensitizing and protective substances in radiation therapy and predictive assays on normal tissues and tumour response...
  46. ncbi request reprint [Radionuclide therapy--a possible way toward an improved treatment of cancer. The obstacle is the shortage of commercially available radionuclides for clinical use]
    Hans Lundqvist
    Rudbecklaboratoriet, Uppsala universitet
    Lakartidningen 101:1000-2, 1005-6. 2004
    ..The article stresses the importance that radionuclides with more suitable emission of particles like 177Lu and 211At are made available for clinical research and routine...
  47. ncbi request reprint EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases
    Qichun Wei
    Department of Radiation Oncology, The Second Affiliated Hospital, Cancer Institute, Zhejiang University School of Medicine, Hangzhou, PR China
    Int J Oncol 31:493-9. 2007
    ..It is also possible that EGFR targeting agents (e.g. Iressa, Tarceva, Erbitux or radiolabelled antibodies) can be applied for therapy of ESCC...
  48. ncbi request reprint Differences in the growth inhibition of cultured K-562 cells by selenium, mercury or cadmium in two tissue culture media (RPMI-1640, Ham's F-10)
    P Frisk
    Department of Oncology, Radiology and Clinical Immunology, Biomedical Radiation Sciences, Uppsala University, Sweden
    Biometals 13:101-11. 2000
    ..The compounds could be ranked according to decreasing toxicity as: methylmercuric chloride > mercuric chloride, cadmium nitrate, sodium selenite > selenomethionine...
  49. ncbi request reprint Pharmacokinetics and experimental PET imaging of a bromine-76-labeled monoclonal anti-CEA antibody
    A Lovqvist
    University PET Center, Uppsala University, Sweden
    J Nucl Med 38:395-401. 1997
    ....
  50. ncbi request reprint Uptake of a boronated epidermal growth factor-dextran conjugate in CHO xenografts with and without human EGF-receptor expression
    P Olsson
    Department of Diagnostic Radiology, Uppsala, Sweden
    Anticancer Drug Des 13:279-89. 1998
    ..In conclusion, after intratumoral injections the conjugate showed receptor-dependent binding to EGFR-rich tumours, and the tumour-to-blood and tumour-to-liver ratios were promising...
  51. ncbi request reprint Positron emission tomography and radioimmunotargeting--aspects of quantification and dosimetry
    M Lubberink
    Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Sweden
    Acta Oncol 38:343-9. 1999
    ..The results indicate that the count rate capabilities of 2D PET permit PET studies for dose evaluation during radioimmunotherapy...
  52. ncbi request reprint Effects of dextranation on the uptake of peptides in micrometastases: studies on binding of EGF in tumor spheroids
    P Nilsson
    Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Tumour Biol 22:229-38. 2001
    ..The obtained differences could not be explained by differences in molecular weight or easily measured physicochemical parameters such as hydrophilic properties or isoelectric point values. Thus, other explanations must be found...
  53. ncbi request reprint The influence of lipophilicity on binding of boronated DNA-intercalating compounds in human glioma spheroids
    L Gedda
    Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Sweden
    Anticancer Drug Des 15:277-86. 2000
    ..The possibility of using these compounds for BNCT are discussed...
  54. ncbi request reprint Uptake and retention of selenite and selenomethionine in cultured K-562 cells
    P Frisk
    Department of Oncology, Radiology and Clinical Immunology, Biomedical Radiation Sciences, Uppsala University, Sweden
    Biometals 13:209-15. 2000
    ..The results indicated a more controlled uptake and retention pattern of selenomethionine compared to selenite...
  55. ncbi request reprint Rejoining of DNA fragments produced by radiations of different linear energy transfer
    B Stenerlow
    Division of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Sweden
    Int J Radiat Biol 76:549-57. 2000
    ..To analyse the rejoining of DNA double-strand breaks (dsb) produced by high-linear energy transfer (LET) ions, with the specific focus on the influence, on the rejoining estimates, of the way dsb are distributed along chromosomes...
  56. ncbi request reprint Binding, internalization and degradation of EGF-dextran conjugates in two human bladder-cancer cell lines
    A Sjostrom
    Biomedical Radiation Sciences, Uppsala University, Sweden
    Int J Cancer 70:383-9. 1997
    ..Several qualities of the 125I-EGF-dextran conjugates might be favourable for targeted radiotherapy...
  57. ncbi request reprint In vivo and in vitro uptake of 111In, delivered with the affibody molecule (ZEGFR:955)2, in EGFR expressing tumour cells
    E Nordberg
    Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, SE 751 85 Uppsala, Sweden
    Oncol Rep 19:853-7. 2008
    ..111In delivered with [111In](ZEGFR:955)2 gave an EGFR specific uptake and the results indicated that the (ZEGFR:955)2 affibody molecule is a candidate for radionuclide-based tumour imaging. Potential therapy applications are discussed...
  58. doi request reprint Cross-fire doses from beta-emitting radionuclides in targeted radiotherapy. A theoretical study based on experimentally measured tumor characteristics
    S A Enger
    Division of Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, SE 751 85 Uppsala, Sweden
    Phys Med Biol 53:1909-20. 2008
    ..Thus, high-energy beta-particles may, in spite of a low self-dose to single clusters, still be favorable to use due to the contribution of inter-cluster cross-fire radiation...
  59. ncbi request reprint Positron emission tomography and radioimmunotargeting--general aspects
    H Lundqvist
    Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Sweden
    Acta Oncol 38:335-41. 1999
    ..The usefulness of these techniques was demonstrated in animal and patient studies by halogen-labelled MAbs and EGF-dextran conjugates and peptides chelated with metal ions...
  60. ncbi request reprint Binding of 125I after administration of 125I-EGF-dextran, 125I-EGF or 125I to human bladder cancer spheroids
    A Sjostrom
    Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Sweden
    Int J Oncol 17:559-64. 2000
    ..The 125I-EGF-dextran was of two different sizes, 28 and 76 kDa, but this did not affect the binding patterns and the results were very similar. The EGF-dextran conjugates had qualities that are of interest for tumour targeting...
  61. ncbi request reprint Closo-dodecaborate(2-) as a linker for iodination of macromolecules. Aspects on conjugation chemistry and biodistribution
    V Tolmachev
    Division of Biomedical Radiation Sciences, Box 535, S 751 21, Uppsala University, Uppsala, Sweden
    Bioconjug Chem 10:338-45. 1999
    ..125I]Iodo-closo-dodecaborate(2-), which is a possible degradation product of [125I]Dx-BS-I, was rapidly excreted in urine without significant accumulation in any organ...
  62. ncbi request reprint Kinetics of 76Br-labeled anti-CEA antibodies in pigs; aspects of dosimetry and PET imaging properties
    A Lovqvist
    Department of Diagnostic Radiology, Uppsala University, Sweden
    Med Phys 26:249-58. 1999
    ..The high energy beta+ spectrum in the 76Br decay had only minor effects on the resolution, but may decrease the quantification accuracy, especially in organs with a lower density such as a lung...
  63. ncbi request reprint Cytotoxicity and subcellular localization of boronated phenanthridinium analogues
    L Gedda
    Department of Diagnostic Radiology, Uppsala University, Sweden
    Anticancer Drug Des 12:671-85. 1997
    ..The hypothesis is that the compounds are trapped in the cellular membranes of viable cells because of their lipophilicity, before reaching nuclear DNA...
  64. ncbi request reprint Preparation and purification of an end to end coupled mEGF-dextran conjugate
    Q Zhao
    Department of Diagnostic Radiology, Uppsala University, Sweden
    Bioconjug Chem 8:927-34. 1997
    ..The conjugate was stable in the pH interval 4-9, in 2 M sodium chloride, in 7 M urea, and in human serum and could still bind to the EGF receptor after such treatments. The conjugates are candidates for targeted nuclide therapy...
  65. ncbi request reprint HER-2--a possible target for therapy of metastatic urinary bladder carcinoma
    Kenneth Wester
    Division of Experimental Urology, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
    Acta Oncol 41:282-8. 2002
    ..These results suggest that HER-2 targeted therapy can be considered as an alternative or a complement to other modalities in the treatment of metastatic urinary bladder carcinoma...
  66. ncbi request reprint Distribution and stability in the rat of a 76Br/125I-labelled polypeptide, epidermal growth factor
    S Scott-Robson
    Department of Radiation Sciences, Uppsala University, Sweden
    Int J Rad Appl Instrum B 18:241-6. 1991
    ..The distribution of both radioisotopes was similar, however, the percentage of 76Br bound to the high molecular weight fraction in the plasma, liver and kidney was greater than that of 125I...
  67. ncbi request reprint Comparative PET imaging of experimental tumors with bromine-76-labeled antibodies, fluorine-18-fluorodeoxyglucose and carbon-11-methionine
    A Lovqvist
    Department of Diagnostic Radiology, Uppsala University, Sweden
    J Nucl Med 38:1029-35. 1997
    ....
  68. ncbi request reprint Expression of EGFR, HER2, HER3, and HER4 in metastatic squamous cell carcinomas of the oral cavity and base of tongue
    T Ekberg
    Otorhinolaryngology and Head and Neck Surgery, Akademiska sjukhuset, Uppsala University, SE 751 85 Uppsala, Sweden
    Int J Oncol 26:1177-85. 2005
    ..g. using radiolabelled antibodies or ligands, and EGFR seemed suitable as target since the expression was high, membrane associated and similar in the primary tumours and the corresponding metastases...
  69. ncbi request reprint Cellular binding of carboranylalanine and some effects of boron neutron capture. Analysis of cultured melanoma B16 cells
    O A Pettersson
    Department of Radiation Sciences, Uppsala University, Sweden
    Acta Oncol 33:685-91. 1994
    ..One explanation might be different intracellular localizations. This has to be studied in more detail...
  70. ncbi request reprint DNA fragmentation by charged particle tracks
    B Stenerlow
    Division of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Adv Space Res 30:859-63. 2002
    ..The results suggest possible roles of both track structure and chromatin organization in the distribution of DNA double-strand breaks along the chromosome...
  71. ncbi request reprint Dose enhancement in fast neutron tumour therapy due to neutron captures in 10B
    J Carlsson
    Department of Radiation Sciences, Uppsala University, Sweden
    Acta Oncol 33:315-22. 1994
    ....
  72. ncbi request reprint High yield direct 76Br-bromination of monoclonal antibodies using chloramine-T
    J Sundin
    Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Sweden
    Nucl Med Biol 26:923-9. 1999
    ..1%, respectively. We conclude that antibodies and peptides can be labeled conveniently with 76Br for the purpose of whole-body tumour imaging by positron emission tomography...
  73. ncbi request reprint Influence of selenium on mercuric chloride cellular uptake and toxicity indicating protection: studies on cultured K-562 cells
    P Frisk
    Department of Oncology, Radiology and Clinical Immunology, Biomedical Radiation Sciences, Uppsala University, Sweden
    Biol Trace Elem Res 81:229-44. 2001
    ..8 x 10(-15) mol/cell of mercury, whereas they survived up to twofold more mercury uptake when exposed to selenite. Selenomethionine gave, with a few exceptions, similar effects as selenite on MC uptake and toxicity...
  74. ncbi request reprint gammaH2AX and cleaved PARP-1 as apoptotic markers in irradiated breast cancer BT474 cellular spheroids
    O F Qvarnström
    Section of Oncology, Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, SE 751 85 Uppsala, Sweden
    Int J Oncol 35:41-7. 2009
    ..However, the more intense and clear staining patterns of gammaH2AX suggests that this marker is preferable for quantification of apoptosis in spheroids and similar paraffin-embedded materials...
  75. ncbi request reprint Effects of an EGFR-binding affibody molecule on intracellular signaling pathways
    E Nordberg
    Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, SE 751 85 Uppsala, Sweden
    Int J Oncol 36:967-72. 2010
    ..This makes the affibody molecule a potentially interesting alternative to cetuximab for EGFR-targeted therapy since it might give different therapy-related effects on tumor cells and different side effects on normal tissues...
  76. ncbi request reprint Effects of the 5-lipoxygenase inhibitors AA-863 and U-60,257 on human glioma cell lines
    I Gati
    Department of Neurology, Uppsala University, Sweden
    Prostaglandins Leukot Essent Fatty Acids 40:117-24. 1990
    ....
  77. ncbi request reprint 76Br-labeled monoclonal anti-CEA antibodies for radioimmuno positron emission tomography
    A Lovqvist
    Department of Radiation Sciences, Uppsala University, Sweden
    Nucl Med Biol 22:125-31. 1995
    ..The biological activity of 76Br-38S1 was retained and comparable to that of chloramine-T labeled 125I-38S1, as tested in vitro...
  78. ncbi request reprint Radioimmunolocalization of hepatic metastases and subcutaneous xenografts from a human colonic cancer in the nude rat. Aspects of tumour implantation site and mode of antibody administration
    A Sundin
    Department of Diagnostic Radiology, Uppsala University, Sweden
    Acta Oncol 32:877-85. 1993
    ..v. MAb administration. The results indicate that tumour implantation site has a quantitative, and the route of administration at least a qualitative impact on the tumour accretion of anti-CEA MAb I-38S1 in the present xenograft model...
  79. ncbi request reprint The narrow proton beam therapy unit at the the Svedberg Laboratory in Uppsala
    A Montelius
    Department of Hospital Physics, University Hospital, Uppsala, Sweden
    Acta Oncol 30:739-45. 1991
    ..In its final form, the proton therapy facility at TSL will harbour a second treatment unit. Here a rotating gantry for 200 MeV protons will provide a broad beam, which will enable treatment of tumours located anywhere in the body...
  80. ncbi request reprint Present status of boron neutron capture therapy
    J Carlsson
    Department of Radiation Sciences, Uppsala University, Sweden
    Acta Oncol 31:803-13. 1992
    ..Increased emphasis will be put on the development of combinations of treatments that fulfil the requirements for attacking the microscopic spread of the tumour...
  81. ncbi request reprint Backscatter radiation at tissue-titanium interfaces. Analyses of biological effects from 60Co and protons
    B Rosengren
    Department of Radiation Sciences, Uppsala University, Sweden
    Acta Oncol 30:859-66. 1991
    ....
  82. ncbi request reprint Quantitative detection in the attomole range for immunochromatographic tests by means of a flatbed scanner
    M Lönnberg
    Center for Surface Biotechnology, Uppsala, S 751 23, Sweden
    Anal Biochem 293:224-31. 2001
    ..3 mm(2) was used for detection and 1% CV when 0.19 mm(2) was used. A flatbed scanner is an inexpensive instrument with multiple uses, which now also includes the sensitive evaluation of immunoassays...